{"entity":{"id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","aka":["MARGARET"],"tldr":"A phase 1/2 trial of TAS0953/HM06 in non-small-cell lung cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.","summary":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities is a phase 1/2 interventional study registered as NCT04683250 by Taiho Pharmaceutical Co., Ltd., with 244 participants planned, started 2020-12-16 and due to reach its primary completion in 2030-03. Interventions recorded: TAS0953/HM06.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04683250","url":"https://clinicaltrials.gov/study/NCT04683250"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","ret-fusion-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04683250","phase":"1/2","setting":"Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","sponsor":"Taiho Pharmaceutical Co., Ltd.","started":"2020-12-16","startedType":"actual","enrolled":244,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04683250/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"}],"company":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/"}]}}